Organisation: Tecfidera

A COMPREHENSIVE SERIES OF ARTICLES ON THIS TOPIC

Johnson & Johnson strikes $30bn deal

US healthcare giant Johnson & Johnson (J&J) has reached agreement to buy Swiss biotech company Actelion in a $30bn (€28bn) all-cash deal that includes spinning off Actelion’s research and development pipeline, the companies said yesterday.

Fri, 27 Jan, 2017

MS drug rejected over cost to HSE

Multiple Sclerosis (MS) Ireland says it is disappointed that an expert group failed to recommend a life-changing drug be made available through the HSE because it costs too much.

Wed, 21 Jan, 2015

MS drug off to impressive launch with $286m sales in third quarter

Biogen Idec yesterday reported $286m (€207m) in third-quarter sales of its high-profile new multiple sclerosis drug Tecfidera, providing fresh evidence that the medicine is off to an impressive launch and exceeding expectations.

Tue, 29 Oct, 2013